After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 ...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Subcutaneous immunotherapy for cancer can cause many of the same side effects as intravenous (IV) immunotherapy because it involves the same medications. Injection site reactions are a common but ...
The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the ...
Alteogen said on the 25th that it signed an exclusive license agreement with Biogen, a U.S. pharmaceutical company, to develop and commercialize subcutaneous injection (SC) formulation biologics based ...
Abivax is advancing obefazimod, a first-in-class oral therapy for UC and CD, with major upcoming data catalysts. Click here ...
Vietnam Investment Review on MSN
Celltrion launches AVTOZMA subcutaneous formulation in US
INCHEON, South Korea, March 16, 2026 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results